Heron Therapeutics (HRTX) Aperçu de l'action
Heron Therapeutics, Inc. est une société de biotechnologie à vocation commerciale qui développe et commercialise des produits thérapeutiques destinés à améliorer les soins médicaux. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
HRTX Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Heron Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.43 |
| Plus haut sur 52 semaines | US$2.14 |
| Plus bas sur 52 semaines | US$0.38 |
| Bêta | 1.65 |
| Variation sur 1 mois | 7.45% |
| Variation sur 3 mois | -55.06% |
| Variation sur 1 an | -78.93% |
| Variation sur 3 ans | -69.29% |
| Variation sur 5 ans | -96.61% |
| Évolution depuis l'introduction en bourse | -99.90% |
Nouvelles et mises à jour récentes
HRTX: Patent Appeal Outcome Will Drive Prospects For Future Profitability
Heron Therapeutics' updated analyst price target of $2 reflects a reset in fair value expectations and a lower assumed future P/E multiple as analysts factor in the recent Cinvanti patent setback along with potential generic competition. Analyst Commentary Recent Street research on Heron Therapeutics highlights a sharp reset in expectations after the Cinvanti patent decision, with analysts reassessing both downside risk from generic competition and any potential upside from an appeal and execution on the existing portfolio.HRTX: Appeal Of Patent Ruling Will Shape Future Profitability Outlook
The analyst price target for Heron Therapeutics has been reduced from $4.75 to $3.00, as analysts factor in the recent Cinvanti patent setback, higher perceived risk, and lower projected profitability, despite a higher assumed future P/E multiple. Analyst Commentary Analyst views on Heron Therapeutics have shifted quickly following the Cinvanti patent decision, with several adjustments to ratings and price targets that reflect both legal risk and revenue concentration in this product.
HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.Recent updates
HRTX: Patent Appeal Outcome Will Drive Prospects For Future Profitability
Heron Therapeutics' updated analyst price target of $2 reflects a reset in fair value expectations and a lower assumed future P/E multiple as analysts factor in the recent Cinvanti patent setback along with potential generic competition. Analyst Commentary Recent Street research on Heron Therapeutics highlights a sharp reset in expectations after the Cinvanti patent decision, with analysts reassessing both downside risk from generic competition and any potential upside from an appeal and execution on the existing portfolio.HRTX: Appeal Of Patent Ruling Will Shape Future Profitability Outlook
The analyst price target for Heron Therapeutics has been reduced from $4.75 to $3.00, as analysts factor in the recent Cinvanti patent setback, higher perceived risk, and lower projected profitability, despite a higher assumed future P/E multiple. Analyst Commentary Analyst views on Heron Therapeutics have shifted quickly following the Cinvanti patent decision, with several adjustments to ratings and price targets that reflect both legal risk and revenue concentration in this product.HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.
HRTX: Reaffirmed 2026 Guidance And Execution Focus May Support Future Upside
Analysts have trimmed their price target on Heron Therapeutics by $2 to reflect updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent commentary on Heron Therapeutics centers on how updated assumptions for discount rates, revenue trajectories, margins and future P/E multiples feed into valuation.HRTX: Revised Profit Outlook And Discount Rate Could Support Future Upside
Analysts have reduced their price target on Heron Therapeutics by $2, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E as the main factors behind the adjustment. Analyst Commentary Recent research points to a more cautious stance on valuation for Heron Therapeutics, with the latest $2 reduction in the price target linked to refreshed assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Heron: Near The Bottom Of A Trading Range Despite Positives
Summary HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031. Read the full article on Seeking AlphaHere's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have had a really impressive month, gaining 27% after a shaky period...Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) missed earnings with its latest third-quarter results, disappointing...Advanced Non-Opioid Therapies Will Transform The Pain Management Market
With both the discount rate and consensus revenue growth forecasts for Heron Therapeutics remaining stable, the consensus analyst price target has consequently held steady at $4.75 per share. What's in the News Reaffirmed Q1 2025 net revenue guidance of $153.0 million to $163.0 million.Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders might have noticed that Heron Therapeutics, Inc. ( NASDAQ:HRTX ) filed its quarterly result this time last...
ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access
Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has softened a substantial 26% over the previous 30 days...Heron Therapeutics: Four Horse Race Of Approved Therapies
Summary Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last "Hold" rating in November 2024. I will evaluate Heron's investment merits based on its full year and Q4 2024 earnings, reported on February 27, 2025. The analysis includes insights from Heron's earnings press release, conference call, 10-Q, and presentation. Heron has demonstrated a variety of successful outcomes, warranting a reassessment of its investment potential. Read the full article on Seeking AlphaHeron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has fared very poorly over the last month, falling by a...Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders would be excited to see that the share price has had a great...Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion. Read the full article on Seeking AlphaHere's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) investors will be delighted, with the company turning in some strong numbers...Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have continued their recent momentum with a 27% gain in the last month...Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...Rendement pour les actionnaires
| HRTX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 1.0% | -3.1% | -0.9% |
| 1Y | -78.9% | 32.8% | 19.4% |
Rendement vs Industrie: HRTX a sous-performé le secteur US Biotechs qui a rapporté 32.8 % au cours de l'année écoulée.
Rendement vs marché: HRTX a sous-performé le marché US qui a rapporté 19.4 % au cours de l'année écoulée.
Volatilité des prix
| HRTX volatility | |
|---|---|
| HRTX Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de HRTX a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de HRTX est passée de 12% à 18% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1983 | 128 | Craig Collard | www.herontx.com |
Heron Therapeutics, Inc. est une société de biotechnologie à vocation commerciale qui développe et commercialise des produits thérapeutiques destinés à améliorer les soins médicaux. Les produits candidats de la société utilisent sa technologie propriétaire Biochronomer, une technologie d'administration de médicaments qui délivre des niveaux thérapeutiques d'une gamme d'agents pharmacologiques à courte durée d'action sur une période allant de quelques jours à quelques semaines avec une seule administration. Elle propose SUSTOL (granisétron), une injection à libération prolongée pour la prévention des nausées et vomissements aigus et différés associés à une chimiothérapie modérément émétisante ou à des schémas de chimiothérapie combinant anthracycline et cyclophosphamide ; et CINVANTI, une formulation intraveineuse d'aprépitant, un antagoniste de la substance P/récepteur de la neurokinine-1, pour la prévention des nausées et vomissements aigus et différés associés à une chimiothérapie anticancéreuse hautement émétisante, ainsi que des nausées et vomissements associés à une chimiothérapie anticancéreuse modérément émétisante.
Heron Therapeutics, Inc. Résumé des fondamentaux
| HRTX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$78.91m |
| Bénéfices(TTM) | -US$30.94m |
| Recettes(TTM) | US$150.71m |
Le site HRTX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| HRTX compte de résultat (TTM) | |
|---|---|
| Recettes | US$150.71m |
| Coût des recettes | US$56.06m |
| Marge brute | US$94.65m |
| Autres dépenses | US$125.59m |
| Les revenus | -US$30.94m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.16 |
| Marge brute | 62.80% |
| Marge bénéficiaire nette | -20.53% |
| Ratio dettes/capitaux propres | 1,550.1% |
Quelles ont été les performances à long terme de HRTX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/14 22:03 |
| Cours de l'action en fin de journée | 2026/07/14 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Heron Therapeutics, Inc. est couverte par 15 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |